Drug Trial Radar · NCT05296447
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
103
Actual
Start
Apr 4, 2022
Primary completion
Jun 2031
Study completion Jun 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- REGENXBIO Inc.
- First posted
- Mar 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.
Conditions
- Diabetic Retinopathy, DR
Interventions
Standard of CareDrug
Standard of Care
AfliberceptDrug
Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)Time frame: 5 years inclusive of the parent study
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona
California Retina Consultants
Bakersfield, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Retinal Diagnostic Center
Los Angeles, California
Northern California Retina Vitreous Associates Medical Group Inc
Mountain View, California
California Eye Specialists Medical Group, Inc
Pasadena, California
Retina Consultants San Diego
Poway, California
California Retina Consultants CRC
Santa Barbara, California
Southeast Retina Center, PC
Augusta, Georgia
University Retina and Macula Associates, PC
Oak Forest, Illinois
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Sierra eye Associates
Reno, Nevada
New Jersey Retina
Teaneck, New Jersey
Vision Research Center Eye Associates of New Mexico
Albuquerque, New Mexico
Duke University
Durham, North Carolina
Mid Atlantic Retina
Philadelphia, Pennsylvania
Charles Retina Institute, P.C
Germantown, Tennessee
Austin Clinical Research
Austin, Texas
Retina Consultants of Texas
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.